Jacob Levi

1.4k total citations
21 papers, 761 citations indexed

About

Jacob Levi is a scholar working on Infectious Diseases, Virology and Economics and Econometrics. According to data from OpenAlex, Jacob Levi has authored 21 papers receiving a total of 761 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 4 papers in Virology and 4 papers in Economics and Econometrics. Recurrent topics in Jacob Levi's work include HIV/AIDS drug development and treatment (8 papers), HIV/AIDS Research and Interventions (7 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Jacob Levi is often cited by papers focused on HIV/AIDS drug development and treatment (8 papers), HIV/AIDS Research and Interventions (7 papers) and SARS-CoV-2 and COVID-19 Research (6 papers). Jacob Levi collaborates with scholars based in United Kingdom, Germany and United States. Jacob Levi's co-authors include Andrew Hill, Katherine Heath, Anton Pozniak, Andrew Hill, Philipp Köhler, Pietro Vernazza, Junzheng Wang, Hannah Wentzel, Shahin Merat and Anna Garratt and has published in prestigious journals such as Clinical Infectious Diseases, Journal of Allergy and Clinical Immunology and AIDS.

In The Last Decade

Jacob Levi

19 papers receiving 747 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jacob Levi United Kingdom 12 538 267 116 105 76 21 761
Patrick G. Clay United States 15 346 0.6× 183 0.7× 134 1.2× 117 1.1× 37 0.5× 41 791
Douglas Shaffer United States 14 260 0.5× 186 0.7× 64 0.6× 104 1.0× 59 0.8× 30 774
James Okuma United States 18 333 0.6× 217 0.8× 113 1.0× 81 0.8× 25 0.3× 41 864
Lindsay Kendall United Kingdom 14 258 0.5× 133 0.5× 75 0.6× 47 0.4× 36 0.5× 30 556
Mohammed Rassool South Africa 11 573 1.1× 325 1.2× 144 1.2× 69 0.7× 56 0.7× 25 764
Zelalem G. Dessie South Africa 9 379 0.7× 95 0.4× 26 0.2× 72 0.7× 29 0.4× 33 666
Pablo Ryan Spain 18 478 0.9× 513 1.9× 60 0.5× 47 0.4× 12 0.2× 104 1.1k
Harjot Singh United States 14 168 0.3× 259 1.0× 20 0.2× 79 0.8× 34 0.4× 50 587
Bingxia Wang United States 21 1.0k 1.9× 675 2.5× 435 3.8× 194 1.8× 94 1.2× 56 1.6k
Erez Battat Israel 11 187 0.3× 169 0.6× 116 1.0× 71 0.7× 57 0.8× 24 736

Countries citing papers authored by Jacob Levi

Since Specialization
Citations

This map shows the geographic impact of Jacob Levi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacob Levi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacob Levi more than expected).

Fields of papers citing papers by Jacob Levi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacob Levi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacob Levi. The network helps show where Jacob Levi may publish in the future.

Co-authorship network of co-authors of Jacob Levi

This figure shows the co-authorship network connecting the top 25 collaborators of Jacob Levi. A scholar is included among the top collaborators of Jacob Levi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacob Levi. Jacob Levi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hill, Andrew, Simiso Sokhela, Bryony Simmons, et al.. (2024). Low CD4 counts predict excessive weight gains during first-line treatment for HIV. Journal of Antimicrobial Chemotherapy. 79(9). 2369–2378. 4 indexed citations
2.
Fairhead, Cassandra, Jacob Levi, & Andrew Hill. (2024). Challenges for Novel Antiretroviral Development in an Era of Widespread tenofovir-disoproxil/lamivudine (or emtricitabine)/dolutegravir availability (TLD) Availability. Clinical Infectious Diseases. 80(2). 434–443. 1 indexed citations
3.
4.
Hill, Andrew, Jacob Levi, Cassandra Fairhead, et al.. (2024). Lenacapavir to prevent HIV infection: current prices versus estimated costs of production. Journal of Antimicrobial Chemotherapy. 79(11). 2906–2915. 13 indexed citations
5.
Levi, Jacob, Junzheng Wang, François Venter, & Andrew Hill. (2023). Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. Obesity. 31(5). 1270–1279. 38 indexed citations
6.
Levi, Jacob, Cassandra Fairhead, & Andrew F. Hill. (2023). Intersections between HIV and obesity in emerging economies. Current Opinion in HIV and AIDS. 19(1). 35–44. 1 indexed citations
7.
Pilkington, Victoria, et al.. (2022). Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. Open Forum Infectious Diseases. 9(9). ofac408–ofac408. 3 indexed citations
8.
Wang, Junzheng, et al.. (2021). Minimum Manufacturing Costs, National Prices, and Estimated Global Availability of New Repurposed Therapies for Coronavirus Disease 2019. Open Forum Infectious Diseases. 9(1). ofab581–ofab581. 17 indexed citations
9.
Wang, Junzheng, et al.. (2021). 407. Minimum Manufacturing Costs, National Prices and Estimated Global Availability of New Repurposed Therapies for COVID-19. Open Forum Infectious Diseases. 8(Supplement_1). S305–S305.
10.
Heath, Katherine, Jacob Levi, & Andrew Hill. (2021). The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture. AIDS. 35(Supplement 2). S197–S203. 93 indexed citations
11.
Levi, Jacob, Junzheng Wang, François Venter, & Andrew Hill. (2021). 891. Minimum Manufacturing Costs and National Prices for Weight Loss Treatments, as Potential Mitigation for Anti-Retroviral Related Weight Gain in HIV. Open Forum Infectious Diseases. 8(Supplement_1). S536–S537. 1 indexed citations
12.
Heath, Katherine, Jacob Levi, & Andrew Hill. (2021). The Joint United Nations Programme on HIV/AIDS 95-95-95 targets: worldwide clinical and cost benefits of generic manufacture.. PubMed. 35(Suppl 2). S197–S203. 63 indexed citations
13.
Heath, Katherine, Jacob Levi, & Andrew Hill. (2020). Reaching UNAIDS 95-95-95 Targets Worldwide: Predicted Benefits and Treatment Costs with Generic Manufacture. SSRN Electronic Journal. 1 indexed citations
14.
Sadeghı, Anahita, Ali Asgari, Alireza Norouzi, et al.. (2020). Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. Journal of Antimicrobial Chemotherapy. 75(11). 3379–3385. 84 indexed citations
15.
Levi, Jacob, et al.. (2020). Rare giant inguinal hernia causing end-stage dialysis-dependent renal failure. BMJ Case Reports. 13(4). e233140–e233140. 2 indexed citations
16.
Moradi, Siavash, Farhang Babamahmoodi, Ahmad Alikhani, et al.. (2020). Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. Journal of Antimicrobial Chemotherapy. 75(11). 3373–3378. 66 indexed citations
17.
Pozniak, Anton, Jacob Levi, Polly Clayden, et al.. (2019). Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy. Clinical Infectious Diseases. 70(12). 2599–2606. 20 indexed citations
18.
Hill, Andrew, Dzintars Gotham, Joseph Fortunak, et al.. (2016). Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment. BMJ Open. 6(1). e009586–e009586. 46 indexed citations
19.
Levi, Jacob, et al.. (2016). Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Global Health. 1(2). e000010–e000010. 227 indexed citations
20.
Lev, Atar, Anthony Simon, Arnon Broides, et al.. (2012). Thymic function in MHC class II–deficient patients. Journal of Allergy and Clinical Immunology. 131(3). 831–839. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Patrick G. Clay Breakdown of academic impact, for papers by Douglas Shaffer Breakdown of academic impact, for papers by James Okuma Breakdown of academic impact, for papers by Lindsay Kendall Breakdown of academic impact, for papers by Mohammed Rassool Breakdown of academic impact, for papers by Zelalem G. Dessie Breakdown of academic impact, for papers by Pablo Ryan Breakdown of academic impact, for papers by Harjot Singh Breakdown of academic impact, for papers by Bingxia Wang Breakdown of academic impact, for papers by Erez Battat
Rankless by CCL
2026